An Analysis of Three Different Prostate Cancer Risk Calculators Applied Before Prostate Biopsy: A Turkish Cohort Validation Study
This article was originally published here
Andrology. November 27, 2021: e14329. doi: 10.1111 / et.14329. Online ahead of print.
The study aimed to investigate the top three risk calculators (ORs) for the Turkish population to predict cancer-free status and high-risk prostate cancer (PCa) in patients undergoing guided transrectal prostate biopsy. by ultrasound. Electronic medical records of 527 patients who underwent a prostate biopsy for the first time due to a PSA of 0.3-50 ng / dl and / or suspected cancer on digital rectal examination (DRE) between January 2017 and December 2020 were retrieved retrospectively. The predictive power of biopsy and surgical cohort CRs was calculated by two urologists using the European Randomized Study of Screening for Prostate Cancer (ERSPC) RC, from the North American Prostate Cancer Prevention Trial-RC (PCPT -RC) and the Prostate Biopsy Collaborative Group (PBCG) -RC. All three CRs were successful in predicting PCa and high-risk disease on ROC analysis (p
PMID: 34837424 | DOI: 10.1111 / et.14329